Navigation Links
Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
Date:7/12/2011

NATICK, Mass., July 12, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt™ Monorail™ Carotid Stent System in combination with its FilterWire EZ™ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery.  The trial began in 2010 and has reached its enrollment goal of 100 patients at 11 sites in Europe.  Principal Investigator of the study is Marc Bosiers, M.D., Head of the Department of Vascular Surgery, A.Z. Sint-Blasius Hospital in Dendermonde, Belgium.  

The Adapt Carotid Stent features thin struts and an innovative design engineered for flexibility in the carotid arteries.  It incorporates a self-expanding, rolled nitinol sheet with patented Dynamic Tapering Technology™ designed to conform to varying carotid anatomies.  This second-generation carotid stent also provides excellent visibility and has a closed-cell geometry that facilitates consistent lesion coverage.  It has been sold in Europe as well as other select countries since receiving CE Mark in 2010.  

"The Adapt Stent offers outstanding deliverability and scaffolding of the vessel wall, which are critical attributes for carotid stents," said Dr. Bosiers.  "I look forward to seeing how the features of this new technology may be reflected in clinical outcomes from the ASTI study."

The study will examine rates of major adverse events -- defined as any death, stroke or myocardial infarction at 30 days.  Additionally, it will assess rates of late ipsilateral stroke, target lesion revascularization and in-stent restenosis.

"Physician experience with the Adapt Stent has been excellent since its introduction in Europe last year," said Jeff Mirviss, President of Boston Scientific's Peripheral Interventions Division.  "It provides physicians with the flexibility, deliverability and lesion coverage needed to treat narrowing in complex carotid anatomies."

In addition to its Adapt Carotid Stent, Boston Scientific markets the Carotid WALLSTENT® Monorail® Endoprosthesis, the leading carotid stent in Europe and Japan and available in all major markets worldwide.  Both stents are mounted on Monorail Delivery Systems and feature closed-cell designs intended to offer increased scaffolding of the vessel wall.  Both stents are also designed to be used in conjunction with the FilterWire EZ Embolic Protection System, intended to capture plaque debris released during the stenting procedure.

"The Adapt Stent is an important addition to our portfolio of leading carotid stents in Europe," said Fred Hrkac, President of Europe, Middle East and Africa at Boston Scientific.  "By offering the only CE Marked, second-generation, closed-cell carotid stent, we plan to build on the success of the Carotid WALLSTENT and continue to provide innovative treatment options for patients with carotid artery disease."  

In the U.S., the Adapt Carotid Stent System is not available for sale.  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific Corporationerik.kopp@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology:
(Date:12/2/2016)... NJ (PRWEB) , ... December 02, 2016 , ... Sourced ... Water has some unique properties including its unmatched natural purity of just 6 ppm ... clean and crisp. , Nothing Water has been available in several ShopRite and FoodTown ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., the ... million in an initial round of funding. The round was led by experienced ... can receive far better care through the application of the best technologies from ...
(Date:12/2/2016)... FL (PRWEB) , ... December 02, 2016 , ... ‘Tis ... are winners of $1,000 each from the National Family Partnership and the Drug Enforcement ... families who decorated their homes and the 10 winning schools who decorated their campuses ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... tech functions and stylish design wanted by today’s consumers at an affordable price, ... Darin Philip says the new watch is “a game changer” when it comes ...
Breaking Medicine News(10 mins):